AMARIN SHARE PRICE / NASDAQ

19.31 USD

-2.08%

October 27, 2025, 15:57 EDT

Invested in the Future of Cardiovascular Medicine

Our purpose is driven by our vision to stop cardiovascular disease from being a leading cause of death worldwide. Amarin is a global pharmaceutical company developing new treatments to fight against cardiovascular disease. Amarin is relentless in its pursuit of scientific breakthroughs that can lead to revolutionary treatments to create a healthier world. Find out more about who we are, what we stand for and how we are making a difference in the lives of patients.

Quarterly Earnings Q3 2025
minus icon
Quarterly Earnings Q2 2025
plus icon
Quarterly Earnings Q4 2024
plus icon

Latest Events and Presentations

Click a link below for access to our events.

29 Oct 2025
Amarin Corporation’s Third Quarter 2025 Results
19 Sep 2025
Amarin Corporate Overview
30 Jul 2025
Amarin Corporation’s Second Quarter 2025 Results
24 Jun 2025
Amarin Corporation’s Investor Conference Call
07 May 2025
Amarin Corporation’s First Quarter 2025 Results
12 Mar 2025
Amarin Corporation’s Fourth Quarter & Full Year 2024 Results
14 Nov 2024
Amarin Corporation’s Virtual Analyst & Investor Day 2024
30 Oct 2024
Amarin Corporation’s Third Quarter 2024 Results
arrow left icon
arrow right icon

Latest News From Amarin

From research results, financial toolkits and webcasts to important investor information and financial governance. Find out the latest financial news about Amarin in these publications.

10/27/2025
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
minus icon
DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the following statement in response to the recent action taken by the U.S.
10/15/2025
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
plus icon
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report third quarter 2025 financial results and conduct a conference call on Wednesday,
10/14/2025
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
plus icon
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian partner HLS Therapeutics, a pharmaceutical company focusing on addressing unmet

Investor Contact Form

For corporate governance, analyst coverage, stock information, secretarial matters and other investor-related queries, please use the Contact form

Financial Information

Balancing Passion with Resolution

Learn more about Amarin’s revenue, expenses, profit and loss, as well as a comprehensive overview of the company’s financial health.

;

Sign-Up for Email Alerts

About Amarin for Investors

Amarin is a leading cardiovascular health pharmaceutical company. As leaders, we apply science, research, passion and global knowledge to ensure we further our vision of stopping cardiovascular disease from being a leading cause of death. In order to achieve this vision, we take a strategic approach to management and financial responsibility.

Corporate Governance

Gain new insights into Amarin’s performance and corporate commitments.

Analyst Coverage

Find out which firms and analysts are covering Amarin.

Stock Information

View real-time stock prices and stock quotes.

Amarin Corporate Overview

Learn more about Amarin corporate overview

About Amarin

A new paradigm in cardiovascular health management

Amarin Corporation is focused on a BOLD vision to stop cardiovascular disease from being a leading cause of death. Find out more about our vision and how we lead the way to better care for those with cardiovascular disease.

Science and Health

Passionate about cardiometabolic science and health

Learn more about the science underpinning our product and research & development efforts to advance innovation in cardiovascular disease.

News and Media

Press releases, news, updates and statements

From reports and reviews to partnerships and innovations, find out more about Amarin's latest news and stories as they stand in the press.

ALL-NP-00016 1/23

Amarin

You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information.

The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.

Amarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.

Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.

This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.

This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.

Information on this website may be revised without any prior notice.